Lorus Therapeutics and Ohio State U Partner on Nanoparticle Delivery of siRNA Cancer Rx

In a collaboration that could produce commercial prospects for both parties, Lorus and OSU will use a $2 million grant from the National Cancer Institute to explore the use of OSU-developed nanoparticle delivery technology with Lorus' siRNA-based oncology drug candidate.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories